This article presents the outcomes of treating stage I and stage III Hodgkin lymphoma patients with proton therapy. Proton therapy led to fewer side effects and after 3 years the relapse free survival was 93% and the event free survival was 87%.
Ackerman Cancer Center
December 2, 2020